keyword
MENU ▼
Read by QxMD icon Read
search

eutos score in CML

keyword
https://www.readbyqxmd.com/read/29200674/effectiveness-of-three-prognostic-scoring-systems-in-predicting-the-response-and-outcome-in-pediatric-chronic-myeloid-leukemia-chronic-phase-on-frontline-imatinib
#1
Ranga Raman Ganta, Srividya Nasaka, Vijay Gandhi Linga, Sadashivudu Gundeti, Lakshmi Srinivas Maddali, Raghunadha Rao Digumarti
Introduction: The Sokal and Hasford (Euro) scores were developed in the chemotherapy and interferon eras and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, European Treatment and Outcome Study (EUTOS) scoring system was introduced. Data on risk stratification in pediatric CML population was lacking due to its rarity (<3%). Objective: To study the effectiveness in predicting the response and outcome with three prognostic scores in pediatric CML-chronic phase patients on front line Imatinib...
July 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29181139/outcome-of-frontline-treatment-with-generic-imatinib-in-adult-patients-with-chronic-myeloid-leukemia-in-algerian-population-a-multicenter-study
#2
B Entasoltan, M A Bekadja, H Touhami, N Mehalhal, Z Zouaoui, N Mesli, M Talbi, A Bachiri, M Michallet
Introduction: In a developing country like Algeria, such expensive therapy is not available. Alternative approaches are needed to help these adult. In Algeria 'imatib' (CIPLA-India) was introduced in 2006; but no study has been published yet in the North Africa region regarding response and outcome of this copy in CML patients. The goal of this multicenter study is to characterize newly adult CML in the western region of Algeria and to assess the effectiveness and safety of imatib (IM, copy) as frontline therapy for patients with CML...
2017: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/28838287/introduction-of-second-generation-tyrosine-kinase-inhibitors-may-reduce-the-prognostic-impact-of-high-risk-patients-according-to-the-european-treatment-and-outcome-study-eutos-score
#3
Eriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, Maho Ishikawa, Tomonori Nakazato, Kei-Ji Sugimoto, Hiroyuki Fujita, Isao Fujioka, Norio Asou, Norio Komatsu, Masahiro Kizaki, Yoshihiro Hatta, Tatsuya Kawaguchi
Our study aims to highlight the critical role of the introduction of second generation tyrosine kinase inhibitors (2nd TKIs) on the prognosis of patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP), as determined by European Treatment and Outcome Study (EUTOS) system. Patients who were diagnosed with CML-CP before March 2009 were classified into the imatinib group, and those diagnosed after April 2009 were classified into the 2nd TKI group. EUTOS high-risk patients exhibited significantly worse outcomes in terms of event-free survival (EFS), progression-free survival (PFS), and CML-associated death than those considered to be low-risk...
August 25, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28761360/analysis-of-clinical-characteristics-and-efficacy-of-chronic-myeloid-leukemia-onset-with-extreme-thrombocytosis-in-the-era-of-tyrosine-kinase-inhibitors
#4
Zhihe Liu, Hongqiong Fan, Yuying Li, Chunshui Liu
The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January 2010 to December 2014 were retrospectively recruited. Based on the platelet (PLT) count, 22 patients were assigned into CML with thrombocytosis (CML-T) group (PLT >1,000×10(9)/L) and 65 patients were classified into CML without extreme thrombocytosis (CML-N) group (PLT ≤1,000×10(9)/L)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28715941/moderate-anemia-at-diagnosis-is-an-independent-prognostic-marker-of-the-eutos-sokal-and-hasford-scores-for-survival-and-treatment-response-in-chronic-phase-chronic-myeloid-leukemia-patients-with-frontline-imatinib
#5
Po-Shen Ko, Yuan-Bin Yu, Yao-Chung Liu, Yi-Tsui Wu, Man-Hsin Hung, Jyh-Pyng Gau, Chia-Jen Liu, Liang-Tsai Hsiao, Po-Min Chen, Tzeon-Jye Chiou, Chun-Yu Liu, Jin-Hwang Liu
OBJECTIVES: This study aimed to examine the prognostic value of anemia for the diagnosis of chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib. METHODS: One hundred and fifty-four CML-CP patients were enrolled. The influences of moderate anemia with hemoglobin (Hb) < 10 g/dl, four scoring systems, and the early molecular response at 3 months (BCR-ABL ≤10%; 3M-EMR) on the achievement of a deep molecular response (DMR, MR4.5), progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) were compared...
August 11, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28502460/can-the-use-of-bone-marrow-parameters-improve-the-efficacy-of-risk-prediction-scores-in-chronic-myeloid-leukemia-in-imatinib-era
#6
Govind Babu Kanakasetty, Aditi Harsh Thanky, Lakshmaiah Kuntegowdanahalli, Lokanatha Dasappa, Linu Jacob, Suresh Babu Mallekavu, Rajeev Lakkavalli, Lokesh Kadabur, Rudresha Antapura
INTRODUCTION: Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with a poorer response to therapy to enable early intensification of treatment. Because the bone marrow (BM) provides a more sensitive reflection of the disease process, we hypothesized that using BM parameters in the Sokal and European Treatment and Outcome Study (EUTOS) risk scores could improve their efficacy in an imatinib-treated population...
March 30, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28286862/consistency-test-between-scoring-systems-for-predicting-outcomes-of-chronic-myeloid-leukemia-in-a-saudi-population-treated-with-imatinib
#7
Haneen R Banjar, Enaam Alsobhi
Inconsistency in prognostic scores occurs where two different risk categories are applied to the same chronic myeloid leukemia (CML) patient. This study evaluated common scoring systems for identifying risk groups based on patients' molecular responses to select the best prognostic score when conflict prognoses are obtained from patient profiles. We analyzed 104 patients diagnosed with CML and treated at King Abdulaziz Medical City, Saudi Arabia, who were monitored for major molecular response (achieving a BCR-ABL1 transcript level equal to or less than 0...
2017: International Scholarly Research Notices
https://www.readbyqxmd.com/read/28194061/performance-of-sokal-and-eutos-scores-for-predicting-cytogenetic-and-molecular-response-in-newly-diagnosed-chronic-myeloid-leukemia-chronic-phase-patients-on-imatinib
#8
Sandip Ganguly, K C Lakshmaiah, Linu Abraham Jacob, Suresh Babu, Lokanatha Dasappa, K S Govind Babu
Sokal index was developed in the pre-imatinib era to predict and prognosticate the outcome of Chronic myeloid leukemia (CML) patients. In the Imatinib era, a new scoring system called EUTOS scoring system has been validated as a predictive marker in CML. The scores have shown variable correlation with complete cytogenetic response (CCyR) and major molecular response (MMR). To assess the performance of Sokal score and EUTOS score as a predictive marker for CCyR and MMR for newly diagnosed CML-CP patients treated with TKIs...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28192602/smokers-with-chronic-myeloid-leukemia-are-at-a-higher-risk-of-disease-progression-and-premature-death
#9
Michael Lauseker, Joerg Hasford, Susanne Saussele, Stephan Kremers, Doris Kraemer, Walter Lindemann, Rüdiger Hehlmann, Markus Pfirrmann
BACKGROUND: Smoking is suspected to not only be a risk factor for chronic myeloid leukemia but an adverse prognostic factor for the disease as well. The objective of the current study was to investigate the impact of smoking on survival and progression to advanced phases of disease. METHODS: Based on the data of the German CML Study IV, the authors analyzed the effect of smoking using a multivariate Cox model with the addition of the European Treatment and Outcome Study (EUTOS) long-term survival score variables of age, spleen size, thrombocytes, and peripheral blasts as well as sex, comorbidities, and type of treatment center...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/27899952/prognostic-and-predictive-implications-of-sokal-euro-and-eutos-scores-in-chronic-myeloid-leukaemia-in-the-imatinib-era-experience-from-a-tertiary-oncology-centre-in-southern-india
#10
Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Govind Babu Kanakasetty, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Rajeev Krishnappa Lakkavalli, Lokesh N Kadabur, Rudresha Antapura Haleshappa
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder. Over the years many prognostic models have been developed to better risk stratify this disease at baseline. Sokal, Euro, and EUTOS scores were developed in varied populations initially receiving various therapies. Here we try to identify their predictive and prognostic implication in a larger population of Indian patients with CML-CP (chronic phase) in the imatinib era.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27818567/the-hasford-score-may-predict-molecular-response-in-chronic-myeloid-leukemia-patients-a-single-institution-experience
#11
Jarosław Dybko, Bożena Jaźwiec, Olga Haus, Donata Urbaniak-Kujda, Katarzyna Kapelko-Słowik, Tomasz Wróbel, Tomasz Lonc, Mateusz Sawicki, Ewa Mędraś, Agnieszka Kaczmar-Dybko, Kazimierz Kuliczkowski
The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score...
2016: Disease Markers
https://www.readbyqxmd.com/read/27751981/changing-treatment-may-affect-the-predictive-ability-of-european-treatment-outcome-study-scoring-for-the-prognosis-of-patients-with-chronic-myeloid-leukemia
#12
Jing Huang, Leyan Wang, Lu Chen, He Qun, Xu Yajing, Chen Fangping, Zhao Xielan
OBJECTIVE: Previous studies compared the predictive ability of the European Treatment Outcome Study (EUTOS), Sokal, and Hasford scoring systems and demonstrated inconsistent findings with unknown reasons. This study was conducted to determine a useful scoring system to predict the prognosis of patients with chronic myeloid leukemia (CML) and identify the probable factors that affect the scoring. MATERIALS AND METHODS: This is a retrospective cohort study. The predictive ability of EUTOS and the factors that affect scoring were analyzed in 234 Chinese chronic-phase CML patients treated with frontline imatinib, including a few patients temporarily administered hydroxyurea for cytoreduction before imatinib...
March 1, 2017: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/27600007/-efficacy-of-three-prognostic-scoring-systems-on-evaluating-the-prognosis-for-patients-with-chronic-myeloid-leukemia
#13
Jing Huang, Xielan Zhao
OBJECTIVE: To retrospectively analyze the efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia (CML) in chronic phase (CP).
 METHODS: In this retrospective cohort study, we collected 234 patients with CML in CP, who were treated with imatinib mesylate (IM). Patients were stratified into low-, intermediate- and high- risk groups according to three scoring systems (Sokal, Hasford and EUTOS), respectively...
August 2016: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/27568522/treatment-and-outcome-of-2904-cml-patients-from-the-eutos-population-based-registry
#14
V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado, A Turkina, D Zackova, G Ossenkoppele, A Zaritskey, M Höglund, B Simonsson, K Indrak, Z Sninska, T Sacha, R Clark, A Bogdanovic, A Hellmann, L Griskevicius, G Schubert-Fritschle, D Sertic, J Guilhot, S Lejniece, I Zupan, S Burgstaller, P Koskenvesa, H Everaus, P Costeas, D Lindoerfer, G Rosti, S Saussele, A Hochhaus, R Hehlmann
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined countries and regions of Europe. Registration time ranged from 12 to 60 months between January 2008 and December 2013. Median age was 55 years and median observation time was 29 months. Eighty percent of patients were treated first line with imatinib, and 17% with a second-generation tyrosine kinase inhibitor, mostly according to European LeukemiaNet recommendations...
March 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27428357/advanced-phase-chronic-myeloid-leukaemia-cml-in-the-tyrosine-kinase-inhibitor-era-a-report-from-the-swedish-cml-register
#15
Stina Söderlund, Torsten Dahlén, Fredrik Sandin, Ulla Olsson-Strömberg, Maria Creignou, Arta Dreimane, Anna Lübking, Berit Markevärn, Anders Själander, Hans Wadenvik, Leif Stenke, Johan Richter, Martin Höglund
OBJECTIVES: The primary goal in management of chronic phase (CP) chronic myeloid leukaemia (CML) is to prevent disease progression to accelerated phase (AP) or blast crisis (BC). We have evaluated progression rates in a decentralised healthcare setting and characterised patients progressing to AP/BC on TKI treatment. METHODS: Using data from the Swedish CML register, we identified CP-CML patients diagnosed 2007-2011 who progressed to AP/BC within 2 yrs from diagnosis (n = 18) as well as patients diagnosed in advanced phase during 2007-2012 (n = 36) from a total of 544 newly diagnosed CML cases...
January 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/27061504/chronic-myeloid-leukaemia-in-spain-its-presentation-characteristics-have-changed-spanish-section-of-the-eutos-population-based-registry
#16
S Osorio, L F Casado, P Giraldo, B Maestro, M Andrade, S Redondo, V García-Gutiérrez, R Ayala, N Garcia, J L Steegmann
OBJECTIVES: To provide more reliable data on the epidemiology of chronic myeloid leukaemia (CML) in Spain than are currently available. MATERIAL AND METHODS: The EUTOS population-based project of European LeukemiaNet is a population registry of new CML cases in patients 18 years of age or older from 22 European areas. The Spanish section included the autonomous communities of Madrid, Castilla-La Mancha and Aragon, from 1-2-2010 to 31-12-2012. RESULTS: A total of 250 cases were recorded in 35 months...
August 2016: Revista Clínica Española
https://www.readbyqxmd.com/read/26925685/significance-of-atm-gene-polymorphisms-in-chronic-myeloid-leukemia-a-case-control-study-from-india
#17
COMPARATIVE STUDY
Manjula Gorre, Prajitha Edathara Mohandas, Sailaja Kagita, Anuradha Cingeetham, Sugunakar Vuree, Sarika Jarjapu, Santhoshirani Nanchari, Phanni Bhushann Meka, Sandhya Annamaneni, Nageswara Rao Dunna, Raghunadharao Digumarti, Vishnupriya Satti
BACKGROUND: Development of chronic myeloid leukemia (CML) involves formation of double strand breaks (DSBs) which are initially sensed by the ataxia telangiectasia mutated (ATM) signal kinase to induce a DNA damage response (DDR). Mutations or single nucleotide polymorphisms in ATM gene are known to influence the signaling capacity resulting in susceptibility to certain genetic diseases such as cancers. MATERIALS AND METHODS: In the present study, we have analyzed -5144A>T (rs228589) and C4138T (rs3092856) polymorphisms of theATM gene through polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) in 925 subjects (476 CML cases and 449 controls)...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/26643920/dasatinib-first-line-multicentric-italian-experience-outside-clinical-trials
#18
MULTICENTER STUDY
Massimo Breccia, Fabio Stagno, Luigiana Luciano, Elisabetta Abruzzese, Mario Annunziata, Mariella D'Adda, Alessandro Maggi, Nicola Sgherza, Antonella Russo-Rossi, Patrizia Pregno, Fausto Castagnetti, Alessandra Iurlo, Roberto Latagliata, Michele Cedrone, Nicola Di Renzo, Federica Sorà, Giovanna Rege-Cambrin, Giorgio La Nasa, Anna Rita Scortechini, Giovanna Greco, Luca Franceschini, Simona Sica, Monica Bocchia, Monica Crugnola, Esther Orlandi, Attilio Guarini, Giorgina Specchia, Gianantonio Rosti, Giuseppe Saglio, Giuliana Alimena
Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies...
January 2016: Leukemia Research
https://www.readbyqxmd.com/read/26416462/prognosis-of-long-term-survival-considering-disease-specific-death-in-patients-with-chronic-myeloid-leukemia
#19
M Pfirrmann, M Baccarani, S Saussele, J Guilhot, F Cervantes, G Ossenkoppele, V S Hoffmann, F Castagnetti, J Hasford, R Hehlmann, B Simonsson
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled the reassessment of prognosis under particular consideration of the probabilities of dying of CML. Analyses were based on 2290 patients with chronic phase CML treated with imatinib in six clinical trials. 'Death due to CML' was defined by death after disease progression. At 8 years, OS was 89%. Of 208 deceased patients, 44% died of CML...
January 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/26392775/comparison-of-the-utility-and-applicability-of-the-sokal-hasford-and-eutos-scores-in-a-population-of-chinese-patients-with-chronic-phase-chronic-myeloid-leukemia-undergoing-imatinib-therapy
#20
Leiming Xia, Wei Qian, Mingzhen Yang, Qingsheng Li, Fei Liu, Yanyan Xie
BACKGROUND: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. AIM: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy. METHODS: We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013...
2015: OncoTargets and Therapy
keyword
keyword
64426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"